Effectiveness and Safety of New Dose of Copaxone® Compared to the Currently Approved Dose

- Relapse-Remitting Multiple Sclerosis
- Completed

Study Title: A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxoneֲ® Compared to Copaxoneֲ® 20mg, the Currently Approved Dose

Teva Identifier: 9006

ClinicalTrials.gov Identifier: NCT00202982

Study Status: Completed

Trial Condition(s): Relapse-Remitting Multiple Sclerosis

Interventions: Drug: glatiramer acetate 20 mg | Drug: glatiramer acetate 40 mg

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age group: Adult

Age Range: 18 Years to 50 Years

Trial Duration: 08/01/2003 - 09/01/2005

Phase: Phase 2

Study Type

Interventional